Remove tag deal
article thumbnail

STAT+: Cepheid faces fresh criticism over the pricing of its TB diagnostics

STAT News

At issue is a TB test developed by Cepheid, which reached a 10-year deal with the WHO in August 2012 to supply its GeneXpert diagnostic to dozens of low- and middle-income countries. per cartridge, a reduction from the previous price tag of $16.86. In exchange for $11.1 Continue to STAT+ to read the full story…

article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. This is closely followed by CB2 receptors in second place. This is followed by epilepsy at 8% of the pipeline and multiple sclerosis at 7% of the pipeline.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cartherics grants licence for CTH-004 to Shunxi

Pharmaceutical Technology

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP.

article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

Grand Rounds March 3, 2023: Adoption, Implementation and Sustainment of Family-focused Prevention in Health Care Systems: How Do We Get There? (Margaret Kuklinski, PhD; Stacy Sterling, DrPH, MSW)

Rethinking Clinical Trials

Across 5 sessions, GGC4H offers strategies for promoting health and wellbeing, such as setting healthy and clear guidelines, positive discipline, dealing with anger constructively, resisting negative influences (with adolescents) and strengthening bonds and building life skills.

article thumbnail

Bristol Myers Squibb pays $475 million for exclusive rights to Dragonfly Therapeutics' IL-12 immunotherapy programme

The Pharma Data

The main focus of the deal is Dragonfly’s monovalent IL-12 immunoglobulin Fc fusion protein known as DF6002, which the company has been investigating in the treatment of both solid and blood cancers.

Protein 52
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Notably, 2022 saw the greatest number of RSA deals arranged, surpassing the previous record in 2017, when the first gene therapy, Novartis’s Kymriah (tisagenlecleucel), was approved and priced at $475,000.